SecBot SecBot

SLDB

Solid Biosciences Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001707502 Biotech & Drug Discovery
$6.48 −0.36 (−5.26%)
Nov 16 4:00 PM ET · prev $6.84
Market cap
$781.3M
Small cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$18.50
+185% · range $11.00–26.00
1 year
+49.3%
from $4.34 · Nov 17
30 days
+9.5%
from $5.92
52-week range
$4.34–11.15
−42% from high · low Nov 17
Avg volume 20D
1.28M
shares / day
Short interest
13.30M
≈11.9% of shares · +8.2%
Days to cover
10.7
at average volume
Insider net
−$2.3M
0 buyers · 7 sellers · since Jan 29
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $2.3M.

  • InstitutionsBULLISH

    Q3 2026: 18 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +8.2% to 13.30M shares. 10.7 days to cover, ≈11.9% of shares.

  • TrendRANGE

    9% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & CODOUBLED1,181,430$8.5M
MORGAN STANLEYDOUBLED1,153,518$8.3M
Qube Research & Technologies LtdDOUBLED1,017,617$7.4M
Invesco Ltd.DOUBLED320,603$2.3M
RHUMBLINE ADVISERSADD168,449$1.2M
ALPS ADVISORS INCADD142,048$1.0M
AMERICAN CENTURY COMPANIES INCADD114,509$827.9K
Russell Investments Group, Ltd.ADD63,928$462.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +185%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026UBS
INITIATE
INITIATEBuy
Sep 16, 2026RBC Capital
INITIATE
INITIATEOutperform
Sep 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 27, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Aug 21, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jun 3, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.3M
sold · 7 insiders
DateInsiderTypeValue
Oct 19, 2026
Brooks Gabriel
Chief Medical Officer
Oct 19, 2026
SELL$24.6K
Oct 18, 2026
Brooks Gabriel
Chief Medical Officer
Oct 18, 2026
EXERCISE9,750 sh
Oct 2, 2026
SMITH IAN F
Director
Oct 2, 2026
EXERCISE3,440 sh
Oct 1, 2026
Ganot Ilan
Director
Oct 1, 2026
AWARD150,000 sh
Jul 2, 2026
SMITH IAN F
Director
Jul 2, 2026
EXERCISE3,440 sh
Jun 10, 2026
Stone Adam Leo
Director
Jun 10, 2026
AWARD77,500 sh
Jun 10, 2026
Ganot Ilan
Director
Jun 10, 2026
AWARD77,500 sh
Jun 10, 2026
Keresty Georgia
Director
Jun 10, 2026
AWARD77,500 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.41-$0.53–-$0.35+6.6%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
13,303,890
shares short
+8.2%
vs prior settlement
10.7
days to cover
≈11.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 Other
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Co
Nov 6, 2026 SEC
RA Capital Management filed Amendment No. 14 to its Schedule 13D for Solid Biosciences, reporting a dilution of its…
SC 13D/A · Impact 3/10
Nov 4, 2026 SEC
Solid Biosciences reported Q3 2026 net loss of $53.9M ($0.36 per share), wider than the $45.8M loss in Q3 2025, as R&D…
PRESS-RELEASE · Impact 4/10
Oct 19, 2026 Insider
Brooks Gabriel sold 4,374 shares
Chief Medical Officer @ $5.62 ($24.6K)
Oct 18, 2026 Insider
Brooks Gabriel acquired via exercise 9,750 shares
Chief Medical Officer
Oct 2, 2026 Insider
SMITH IAN F acquired via exercise 3,440 shares
Director
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · DOUBLED
1,181,430 shares ($8.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 10, 2026
Press release
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company…
Nov 4, 2026
Earnings
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of…
Nov 2, 2026
Earnings date
SLDB Q3 2026 Earnings Scheduled · 2026-11-02
Oct 30, 2026
Short interest
Short Interest: SLDB up 8% to 13.3M shares
Settlement 2026-10-30 | Days to cover: 10.71 | ≈11.92% of shares outstanding (est.)
Oct 1, 2026
Press release
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing…

SecBot reports

9 filings · 5 press releases · 1 bullish · 2 bearish · 6 neutral
All SLDB filing & press-release reports (14)